Five-year follow-up of drug utilization for secondary prevention in coronary artery disease
- 100 Downloads
Objective Despite the availability of various prevention guidelines on coronary artery disease, secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal. In this study, we aimed to assess the guideline adherence of secondary prevention prescribing and the continuity of adherence for a 5-year period in a small cohort of patients angiographically diagnosed to have coronary artery disease. Method In this prospective study, 73 patients who were angiographically diagnosed to have CAD were followed up for 5 years. The baseline demographic and clinical data were collected just before angiography. The baseline drug data were collected at the day of discharge. The fifth year data were taken from the patients via face-to-face consultations or phone interviews. Results The ‘initial prescribing rate’ at discharge was found to be 82% for aspirin, 49% for statins, 44% for ACE inhibitors and 55% for beta-blockers. ‘Continuity of prescribing’ for 5 years was 45% for aspirin, 26% for statins, 17% for ACE inhibitors and 20% for beta-blockers. Conclusions Besides the sub-optimal prescribing of secondary prevention drugs, absence of continuity of prescribing seems to be a challenging issue in pharmaceutical care of coronary artery disease patients.
KeywordsDrug Utilisation Follow up Guideline Secondary prevention Coronary disease Turkey
The study was carried out with no external funding.
Conflict of interest
The authors have no conflicts of interest.
- 1.AHA; ACC; National Heart, Lung, and Blood Institute, Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–9.Google Scholar
- 5.World Health Organization. World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999.Google Scholar
- 13.Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):1–72.Google Scholar
- 14.Dirican RM. Community medicine courses (in Turkish). Ankara:Hatipoglu Yayinevi;1990. 1012.Google Scholar
- 18.American Pharmaceutical Association. Principles of practice for pharmaceutical care. Washington, DC: American Pharmaceutical Association; 1995.Google Scholar
- 20.Kelly J, Forrest F, Hudson S. A patient-held medication record and a patient medication profile to support the continuity of acute cancer care. Int J Pharm Pract. 2001;9(suppl):R40.Google Scholar